Sign inJoin waitlistJoin the waitlist

Hagop Kantarjian

, Chair · University of Texas M D Anderson Cancer Center

Credentials: · · · · ·

History

University of Texas M D Anderson Cancer Center
Present
Leukemia Department · University of Texas M D Anderson Cancer Center
Present
The University of Texas System
Present

Medical Oncology
University of Texas Health Science Center at Houston
1980–1983
American University of Beirut
1978–1980
Doctor of Medicine
1975–1979

Research

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
New England Journal of Medicine · 2001 · 4,052 citations
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
Review · Leukemia · 2022 · 3,530 citations
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
New England Journal of Medicine · 2003 · 2,741 citations

Jorge Cortes
943 papers · 21 as a fellow
Elias Jabbour
740 papers · 17 as a fellow
Guillermo Garcia-Manero
721 papers · 1 as a fellow
SO
Susan O'Brien
674 papers
Tapan Kadia
438 papers · 1 as a fellow
GB
Gautam Borthakur
425 papers
MK
Michael Keating
403 papers
Naval Daver
373 papers · 1 as a fellow
SV
Srdan Verstovsek
315 papers · 53 as a fellow
Courtney DiNardo
311 papers · 2 as a fellow
Marina Konopleva
311 papers
FG
Francis Giles
301 papers

Grants

SPORE University of Texas M. D. Anderson Cancer Center-Leukemia
National Cancer Institute · P50
Contact PI · $21.1M · University of Tx Md Anderson Can Ctr
2003–2018
New Approaches to the Biology and Treatment of Myelodysplastic Syndromes (MDS)
National Cancer Institute · P01
Contact PI · $3.9M · University of Tx Md Anderson Can Ctr
2005–2011
The Therapy of CML
National Cancer Institute · P01
Project lead · $275.2K · University of Tx Md Anderson Can Ctr
1997–2001
Clin. and Lab. Investigations of New Agents in Leukemia
National Cancer Institute · R55
Contact PI · $100K · University of Tx Md Anderson Can Ctr
1992–1994

Clinical trials

Guadecitabine With or Without Idarubicin or Cladribine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
Principal investigator · Completed · Phase 2
M.D. Anderson Cancer Center
2014–2020
Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors
Principal investigator · Terminated · Phase 1
M.D. Anderson Cancer Center
2013–2019
Bendamustine in Acute Lymphoblastic Leukemia/Lymphoma (ALL)
Principal investigator · Withdrawn · Phase 2
M.D. Anderson Cancer Center
2012
Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
Principal investigator · Completed · Phase 2
Amgen Research (Munich) GmbH
2011–2017